What is Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals is a biopharmaceutical company dedicated to developing medicines that treat intractable diseases by silencing the genes that cause them. Leveraging a comprehensive portfolio of RNA chemistries and advanced delivery methods, Arrowhead's therapeutic candidates aim to induce rapid, deep, and durable knockdown of target genes. The company's approach is rooted in RNA interference (RNAi), a natural cellular mechanism that inhibits gene expression and, consequently, protein production. This innovative strategy positions Arrowhead at the forefront of genetic medicine, targeting diseases that have historically been difficult to treat.
How much funding has Arrowhead Pharmaceuticals raised?
Arrowhead Pharmaceuticals has raised a total of $500M across 1 funding round:
Debt
$500M
Debt (2024): $500M with participation from Sixth Street
Key Investors in Arrowhead Pharmaceuticals
Sixth Street
Sixth Street is a global investment firm with substantial assets under management, known for its investments in prominent technology and entertainment companies. Their participation in Arrowhead's funding round highlights a strategic focus on innovative healthcare and biotechnology ventures.
What's next for Arrowhead Pharmaceuticals?
The recent major enterprise-level funding and strategic investment signal a pivotal phase for Arrowhead Pharmaceuticals. This capital infusion is expected to accelerate the advancement of its RNAi-based therapeutics through clinical trials and towards commercialization. The company's focus on silencing disease-causing genes suggests a strategic expansion into new therapeutic areas and a deepening of its existing pipeline. With a robust technological platform and a clear therapeutic strategy, Arrowhead is poised for significant growth and impact in the biopharmaceutical sector.
See full Arrowhead Pharmaceuticals company page
